Scroll

chlortalidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	625	77-36-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clortalidone phthalamudine chlorphthalidolone chlorthalidone chlorthalidon chlortalidone	A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. Molecular weight: 338.76 Formula: C14H11ClN2O4S CLOGP: 0.45 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 109.49 ALOGS: -3.81 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clortalidone
phthalamudine
chlorphthalidolone
chlorthalidone
chlorthalidon
chlortalidone

A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.

Molecular weight: 338.76
Formula: C14H11ClN2O4S
CLOGP: 0.45
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 109.49
ALOGS: -3.81
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	O
25	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	65 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	36 hours	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	3.90 L/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.46 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	1.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.24 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.12 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 7, 1960	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	154.53	13.97	142	11436	111758	63365686
Hypokalaemia	61.78	13.97	85	11493	103719	63373725
Pneumonia viral	59.46	13.97	29	11549	7893	63469551
Cardiac murmur	52.87	13.97	33	11545	14519	63462925
Presyncope	51.95	13.97	42	11536	27743	63449701
Blood pressure increased	49.24	13.97	98	11480	161964	63315480
Breath sounds abnormal	47.91	13.97	28	11550	10945	63466499
Systemic infection	37.82	13.97	18	11560	4642	63472802
Milk-alkali syndrome	36.33	13.97	11	11567	817	63476627
Myxoedema coma	33.67	13.97	9	11569	426	63477018

Showing 1 to 10 of 46 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Meningitis aseptic	108.93	16.80	37	7906	3187	34945801
Renal artery stenosis	96.67	16.80	31	7912	2230	34946758
Hyponatraemia	94.93	16.80	105	7838	82586	34866402
Rectal prolapse	94.35	16.80	22	7921	470	34948518
Renal cyst haemorrhage	88.63	16.80	22	7921	617	34948371
Intraductal papillary mucinous neoplasm	82.21	16.80	20	7923	515	34948473
SARS-CoV-2 antibody test positive	81.52	16.80	19	7924	405	34948583
Hypokalaemia	79.30	16.80	81	7862	58133	34890855
Abdominal wall haemorrhage	73.67	16.80	18	7925	472	34948516
Vena cava injury	69.43	16.80	16	7927	324	34948664

Showing 1 to 10 of 59 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	244.26	13.47	238	16268	177610	79550272
Hypokalaemia	116.16	13.47	146	16360	143894	79583988
Renal artery stenosis	109.48	13.47	37	16469	3445	79724437
Presyncope	94.78	13.47	74	16432	40980	79686902
Renal cyst haemorrhage	88.91	13.47	22	16484	670	79727212
SARS-CoV-2 antibody test positive	82.62	13.47	19	16487	420	79727462
Intraductal papillary mucinous neoplasm	76.11	13.47	20	16486	778	79727104
Vena cava injury	70.35	13.47	16	16490	336	79727546
Abdominal wall haemorrhage	69.11	13.47	18	16488	676	79727206
Rectal prolapse	64.00	13.47	22	16484	2156	79725726

Showing 1 to 10 of 94 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C03BA04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides, plain
ATC	C03BB04	CARDIOVASCULAR SYSTEM DIURETICS LOW-CEILING DIURETICS, EXCL. THIAZIDES Sulfonamides and potassium in combination
ATC	C03EA06	CARDIOVASCULAR SYSTEM DIURETICS DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION Low-ceiling diuretics and potassium-sparing agents
FDA EPC	N0000175420	Thiazide-like Diuretic
FDA PE	N0000175359	Increased Diuresis
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004232	Diuretics
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D045283	Natriuretic Agents

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Edema	indication	267038008
Pulmonary Edema due to Chronic Heart Failure	indication
Peripheral Edema due to Chronic Heart Failure	indication
Diabetes insipidus	off-label use	15771004	DOID:9409
Calcium renal calculus	off-label use	427649000
Anuria	contraindication	2472002	DOID:2983
Suicidal thoughts	contraindication	6471006
Psoriasis	contraindication	9014002	DOID:8893
Peptic ulcer	contraindication	13200003	DOID:750

Showing 1 to 10 of 53 entries

Previous1 2 3 4 5 6Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.63	acidic
pKa2	9.38	acidic
pKa3	13.47	acidic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 40MG MEDOXOMIL;12.5MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	7572920	Jan. 7, 2025	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;12.5MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	7572920	Jan. 7, 2025	TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG	EDARBYCLOR	AZURITY	N202331	Dec. 20, 2011	RX	TABLET	ORAL	9387249	July 1, 2031	TREATMENT OF HYPERTENSION

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Solute carrier family 12 member 3	Transporter	P55017	S12A3_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	6.46	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	6.71	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	7.64	CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	8.35	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	6.04	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	8.05	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.55	CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	4.96	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	5.87	CHEMBL

Showing 1 to 10 of 13 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
KLT	PDB_CHEM_ID
002309	NDDF
1125	INN_ID
2409	RXNORM
2732	PUBCHEM_CID
387324004	SNOMEDCT_US
4017887	VUID
4017887	VANDF
4364	MMSL
4432	MMSL

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	0591-5782	TABLET	25 mg	ORAL	ANDA	18 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	0591-5783	TABLET	25 mg	ORAL	ANDA	18 sections
ATENOLOL AND CHLORTHALIDONE	HUMAN PRESCRIPTION DRUG LABEL	2	10135-733	TABLET	25 mg	ORAL	ANDA	21 sections
ATENOLOL AND CHLORTHALIDONE	HUMAN PRESCRIPTION DRUG LABEL	2	10135-734	TABLET	25 mg	ORAL	ANDA	21 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-936	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-936	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-937	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	16714-937	TABLET	25 mg	ORAL	ANDA	16 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	21695-743	TABLET	25 mg	ORAL	ANDA	18 sections
Atenolol and Chlorthalidone	HUMAN PRESCRIPTION DRUG LABEL	2	21695-744	TABLET	25 mg	ORAL	ANDA	18 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next